Overview TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) Status: Recruiting Trial end date: 2024-12-01 Target enrollment: Participant gender: Summary This is a study to assess the safety of TQB3909 monotherapy in participants with relapsed or refractory MCL. Phase: Phase 1/Phase 2 Details Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.